dual anti-CD20 chimeric costimulatory receptor/anti-CSPG4 CAR T-cell therapy (Miltenyi Biotec)

N/A

Report date: 2025/03/19 08:58:29

Base Information

Drug Namedual anti-CD20 chimeric costimulatory receptor/anti-CSPG4 CAR T-cell therapy (Miltenyi Biotec)

Drug Alias Nameanti-CSPG4 CARgG4 Hinge-CH2-CH3

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsChondroitin sulfate proteoglycan 4 modulators

TargetsChondroitin sulfate proteoglycan 4B-lymphocyte antigen CD20

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMiltenyi GmbH

China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi GmbH

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A